BlossomHill Therapeutics Prices Upsized $150M IPO at $16 for EGFR NSCLC Programs

BlossomHill Therapeutics (BLSM) priced its upsized initial public offering at $16.00 per share, selling 9,375,000 shares for $150 million in gross proceeds. Shares begin trading on the Nasdaq Global Select Market today, August 7, under the ticker BLSM. Underwriters led by J.P. Morgan, Leerink Partners, and Guggenheim have a 30-day option for up to 1,406,250 additional shares.

The raise was upsized from an initial $125 million target. The $16 final price sits at the midpoint of the $15-$17 range. BlossomHill is one of two biotech IPOs debuting today, alongside Latigo Biotherapeutics ($345.6 million), bringing August’s biotech IPO total to more than $1.1 billion across four companies including Braveheart Bio and Attovia Therapeutics.

The San Diego-based company is advancing two clinical-stage oncology programs. The lead asset, BH-30643, is a non-covalent macrocyclic OMNI-EGFR inhibitor designed to be mutant-selective. It targets EGFR kinase domain mutations while sparing wild-type EGFR, potentially reducing the dose-limiting toxicities that constrain earlier-generation TKIs like Tagrisso. Standard EGFR inhibitors bind to the ATP-binding pocket and are overcome by secondary mutations; BH-30643’s macrocyclic structure is engineered to maintain binding across a broader range of resistance mutations. BH-30643 is currently in the Phase 1/2 SOLARA trial (NCT06706076) for patients with locally advanced or metastatic NSCLC harboring EGFR or HER2 mutations.

The second program, BH-30236, is a CLK inhibitor targeting relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes. The hematologic malignancy space has few targeted options but carries a higher risk of single-agent failure than biomarker-driven solid tumor programs.

The risk is straightforward: both programs are Phase 2 at best. BH-30643’s SOLARA trial is dose-escalation with backfill cohorts — early, not registrational. The company has roughly two to three years of cash runway at current burn rates before needing additional financing or a partnership. The EGFR TKI market is crowded, with Tagrisso (osimertinib) dominating first-line and Rybrevant (amivantamab) establishing a foothold in later lines. BlossomHill must show clinically meaningful responses in Tagrisso-resistant patients to justify a registrational path.

What to watch next: SOLARA Phase 1 data, expected at a medical meeting, and any signs that BH-30643’s mutant-selectivity profile translates to better tolerability than existing EGFR inhibitors in resistant patients.

What It Means for the Trade

Fresh biotech IPOs are momentum instruments, not investments, and BLSM is now in that regime: a $150 million raise at a sub-$1 billion valuation, two early-stage assets, and a syndicate (J.P. Morgan, Leerink, Guggenheim) that will want to show the tape strength into the first data drop. The pattern that matters post-IPO is lockup-to-catalyst sequencing: SOLARA Phase 1 data is the near-term event, and the lockup expiry (typically ~180 days, so early 2027) is the structural overhang. If data lands well before lockup, the stock holds; if the calendar inverts, you get the classic post-IPO air pocket.

The honest valuation framing: this is an option on one molecule. BH-30643’s bull case is the post-Tagrisso resistance population — EGFR-mutant NSCLC patients who progress on osimertinib, a population measured in the low hundreds of thousands globally and growing every year as first-line osimertinib use expands. Tagrisso did roughly $6-plus billion at peak, and the resistance setting has no approved targeted therapy for the majority of mechanisms (C797S, MET amplification, small-cell transformation each need different answers). A best-in-class pan-mutant inhibitor that also tolerates better would be a franchise. That’s the pitch. It is, right now, a Phase 1/2 pitch with dose-escalation data.

What the macro tape gave this deal: August 2026 has been a biotech IPO window (four-plus deals, $1.1 billion-plus raised, including Latigo’s $345.6 million the same day). Windows close. If SOLARA data disappoints or the tape turns, BLSM’s balance sheet (roughly 2-3 years runway) still forces the next raise into whatever market exists then. Trade the catalyst, don’t marry the balance sheet.

Program Context: What BH-30643 Actually Has to Beat

Be specific about the competitive set, because “EGFR inhibitor” covers twenty years of drugs. First-line is Tagrisso’s fortress — osimertinib holds the FLAURA2-anchored standard, and Johnson & Johnson’s Rybrevant (amivantamab) plus chemo is taking first-line share in EGFR exon 20 and now broader populations after MARIPOSA. The resistance setting is fragmented: chemotherapy, Rybrevant-based combos post-TKI, and a pipeline of fourth-generation TKIs (BLU-945 lineage, BBT-176 lineage, and a dozen Chinese-developed mutants-selective inhibitors) all chasing C797S-containing genotypes. That’s the pool BH-30643 swims in.

Its differentiation claims are two: non-covalent macrocyclic binding (broader resistance-mutation coverage than covalent inhibitors that need the C797 cysteine intact) and wild-type EGFR sparing (lower rash/diarrhea than first-gen and pan-HER inhibitors). The macrocyclic non-covalent approach echoes EAI-class allosteric inhibitors and the chemotype logic behind BDTX-1535-type assets — the concept is validated as chemistry, unvalidated as medicine. SOLARA’s backfill cohorts in Tagrisso-resistant patients will show response rates first; duration and tolerability decide whether a registrational path opens.

The second program, BH-30236 (CLK inhibitor in relapsed AML/high-risk MDS), is really an option on an option. CLK3/splicing-axis inhibitors are mechanistically interesting (myeloid blasts are addicted to altered splicing programs) but no CLK inhibitor has registered anywhere, and single-agent activity in heavily pretreated AML is a graveyard. It contributes pipeline-slide bulk, not valuation, at this stage.

Risks and What Could Go Wrong

The full checklist for an early-stage oncology IPO: (1) SOLARA response rates underwhelm — in unselected resistant populations, single-agent ORRs below ~30% with short duration make the registrational math hard against chemo-combo comparators; (2) tolerability doesn’t separate — if the wild-type-sparing design doesn’t produce a visibly cleaner rash/diarrhea/stomatitis profile, the whole mutant-selectivity pitch loses its commercial logic, since oncologists already accept Tagrisso-class toxicity; (3) the fourth-generation field closes the window — multiple C797S-directed candidates are ahead in development, and first-mover in that setting takes the prospective partner interest; (4) dilution path — a company this size funding a registrational program will need a partner or a follow-on, and either at a weak moment is painful; (5) IPO-tape beta — small-cap biotech in September after an August window is hostage to sector risk-off flows that have nothing to do with SOLARA.

None of these are exotic risks; they’re the base rates of Phase 1/2 oncology. The discipline is sizing: this is a lottery-ticket allocation until SOLARA shows human efficacy, and the interesting decision point comes the morning after the first data presentation, not before.